Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $29,969.63 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 28,009 shares of Werewolf Therapeutics stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $1.07, for a total transaction of $29,969.63. Following the completion of the transaction, the director owned 2,907,986 shares of the company’s stock, valued at $3,111,545.02. This represents a 0.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Friday, December 12th, Luke Evnin sold 17,858 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.08, for a total value of $19,286.64.
• On Wednesday, December 10th, Luke Evnin sold 37,104 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.06, for a total value of $39,330.24.
• On Tuesday, December 9th, Luke Evnin sold 44,570 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.01, for a total value of $45,015.70.
• On Monday, December 8th, Luke Evnin sold 34,041 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total value of $33,700.59.
• On Friday, December 5th, Luke Evnin sold 16,568 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $16,070.96.
• On Thursday, December 4th, Luke Evnin sold 53,416 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $51,813.52.
• On Wednesday, December 3rd, Luke Evnin sold 36,726 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.87, for a total value of $31,951.62.
• On Tuesday, December 2nd, Luke Evnin sold 38,043 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $33,858.27.
• On Monday, December 1st, Luke Evnin sold 39,096 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $36,750.24.
• On Friday, November 28th, Luke Evnin sold 13,014 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.99, for a total transaction of $12,883.86.

Werewolf Therapeutics Price Performance

Werewolf Therapeutics stock traded up $0.01 during midday trading on Friday, reaching $1.10. 368,752 shares of the stock were exchanged, compared to its average volume of 501,947. Werewolf Therapeutics, Inc. has a 52 week low of $0.60 and a 52 week high of $2.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 3.87 and a current ratio of 3.87. The firm has a market cap of $53.39 million, a PE ratio of -0.68 and a beta of 0.74. The company’s fifty day moving average is $1.30 and its 200-day moving average is $1.33.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. On average, sell-side analysts forecast that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HOWL. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Bank of America decreased their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. JMP Securities lowered their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $7.75.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of large investors have recently modified their holdings of HOWL. Quadrature Capital Ltd purchased a new position in shares of Werewolf Therapeutics during the 2nd quarter valued at about $28,000. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics during the second quarter valued at approximately $48,000. Nuveen LLC purchased a new position in shares of Werewolf Therapeutics during the first quarter worth approximately $71,000. AQR Capital Management LLC purchased a new position in shares of Werewolf Therapeutics during the first quarter worth approximately $79,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth approximately $92,000. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.